Retatrutide 16mg

Retatrutide is a first-in-class triple hormone receptor agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. With a molecular formula of C221H342N46O68, molecular weight of 4731.4 g/mol, and CAS number 2381089-83-2, it represents a novel approach to metabolic research.

Research has demonstrated that retatrutide’s triple agonism produces distinct metabolic effects beyond what dual agonists achieve. The glucagon receptor component increases energy expenditure through hepatic lipid oxidation and thermogenesis, while GIP and GLP-1 receptor activation provides complementary effects on insulin secretion, appetite regulation, and gastric motility. Phase 2 clinical data showed unprecedented weight reduction compared to existing peptide therapies.

Preclinical studies reveal retatrutide significantly reduces hepatic triglyceride content and improves markers of non-alcoholic steatohepatitis (NASH). The glucagon component drives hepatic fat mobilization and amino acid catabolism, while the incretin components maintain glycemic control despite glucagon-mediated hepatic glucose output. This balance makes it a compound of significant research interest in metabolic disease models.

Each vial contains 16mg of lyophilized retatrutide at greater than 99.9% purity, verified by independent HPLC and mass spectrometry. Supplied as a sterile lyophilized powder.